Early observations and pilot data that first suggested a new direction
Historically, all children with a first febrile urinary tract infection underwent voiding cystourethrography (VCUG) to detect vesicoureteral reflux (VUR), based on the assumption that reflux led to renal scarring and chronic kidney disease. This bottom-up approach exposed hundreds of thousands of children annually to invasive catheterization with modest diagnostic yield. NICE challenged this paradigm in 2007 with a top-down approach, recommending DMSA renal scintigraphy first and reserving VCUG only for children with proven renal involvement. Early observational data suggested that most low-grade VUR resolved spontaneously and did not cause clinically significant renal damage.
Landmark RCTs and pivotal trials that established the evidence base
The AAP published its revised 2011 guideline limiting routine VCUG after a first febrile UTI in children aged 2-24 months, recommending renal/bladder ultrasound as the initial imaging study and reserving VCUG for those with ultrasound abnormalities or recurrent UTI. This was supported by evidence that low-grade VUR (grades I-III) rarely caused significant renal scarring. The landmark RIVUR trial (2014) randomized 607 children with VUR to antibiotic prophylaxis versus placebo and found that while prophylaxis reduced recurrence by 50%, it did not reduce renal scarring. This challenged the fundamental premise that detecting and treating VUR prevents renal damage.
Follow-up studies, subgroup analyses, and real-world validation
The PRIVENT trial from Australia examined antibiotic prophylaxis in children with recurrent UTI regardless of VUR status, finding a modest reduction in recurrence (NNT=14) but no impact on renal scarring. The Swedish Reflux Trial compared endoscopic injection, prophylaxis, and surveillance for dilating VUR, finding no difference in renal outcomes at 2 years. Multiple quality improvement studies demonstrated successful de-implementation of routine VCUG with 40-60% reductions in unnecessary imaging without increases in missed diagnoses. Contrast-enhanced voiding urosonography (ceVUS) emerged as a radiation-free alternative to fluoroscopic VCUG when reflux imaging is needed.
Integration into clinical practice guidelines and recommendations
The AAP 2011 guideline (reaffirmed 2016) established the current selective imaging approach: renal and bladder ultrasound after first febrile UTI in children 2-24 months, with VCUG reserved for abnormal ultrasound, recurrent UTI, or atypical clinical features. NICE takes an even more restrictive approach, stratifying imaging by age group and clinical severity. The EAU/ESPU pediatric urology guidelines align with selective imaging. These guidelines collectively shifted practice from detecting all reflux to identifying only clinically significant urinary tract abnormalities.
AAP Clinical Practice Guideline: Urinary Tract Infection in Febrile Infants and Children 2-24 Months
Obtain renal/bladder ultrasound after first febrile UTI. Do not perform routine VCUG unless ultrasound reveals hydronephrosis, scarring, or other findings suggesting high-grade VUR or obstructive uropathy, or in cases of recurrent febrile UTI.
NICE Guideline CG54: Urinary Tract Infection in Under 16s
Imaging stratified by age, severity, and recurrence. Ultrasound during acute episode only for atypical UTI. DMSA 4-6 months after atypical or recurrent UTI. VCUG only if DMSA shows scarring or in infants <6 months with atypical/recurrent UTI.
Now
Current standard of care and ongoing research directions
The imaging approach to febrile UTI in children has been successfully de-escalated, with VCUG rates dropping significantly since 2011. Current practice relies on renal ultrasound as the primary imaging modality after a first febrile UTI, with VCUG reserved for selected cases. Ongoing debates center on whether any imaging beyond ultrasound is needed after a first uncomplicated UTI, the role of contrast-enhanced voiding urosonography (ceVUS) as a radiation-free alternative, and whether novel biomarkers (procalcitonin, NGAL) can better predict renal involvement. The paradigm has shifted from reflexive VCUG to thoughtful, risk-stratified imaging that minimizes invasive procedures without compromising detection of significant urinary tract anomalies.
Why did practice change away from routine VCUG for all children with UTI?+
Evidence showed that most low-grade VUR resolves spontaneously and does not cause clinically significant renal scarring. The RIVUR trial demonstrated that even treating VUR with prophylactic antibiotics did not reduce scarring. Routine VCUG exposed many children to invasive catheterization with low diagnostic yield for actionable findings.
Does vesicoureteral reflux still matter clinically?+
High-grade VUR (grades IV-V) remains clinically significant and may require intervention. However, low-grade VUR (I-III) is now understood to be a common developmental variant that usually resolves with growth and has minimal impact on long-term renal outcomes in the absence of recurrent infections.
What is the role of antibiotic prophylaxis in children with VUR?+
The RIVUR trial showed prophylaxis reduces UTI recurrence by about 50% but does not prevent renal scarring. Current guidelines suggest prophylaxis may be considered for children with recurrent febrile UTIs or high-grade VUR, but it is no longer recommended for all children with any grade of reflux.
